Aspirin, chronic hepatitis B (CHB) and hepatocellular carcinoma (HCC)-will there ever be enough data?
- PMID: 37181340
- PMCID: PMC10170279
- DOI: 10.21037/atm-23-205
Aspirin, chronic hepatitis B (CHB) and hepatocellular carcinoma (HCC)-will there ever be enough data?
Keywords: Aspirin; chronic hepatitis B (CHB); hepatocellular carcinoma (HCC); prevention.
Conflict of interest statement
Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-23-205/coif). The authors have no conflicts of interest to declare.
Comment on
-
Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis.Hepatology. 2022 Aug;76(2):492-501. doi: 10.1002/hep.32380. Epub 2022 Mar 17. Hepatology. 2022. PMID: 35100447
References
-
- World Health Organization. Global hepatitis report 2017. World Health Organization, 2017.
Publication types
LinkOut - more resources
Full Text Sources